

No: 20/2026/CV-MP

Hanoi, June 17, 2026

INFORMATION DISCLOSURE

To: - State Securities Commission;

- Hanoi Stock Exchange

1. Company Name: **MEDIPLANTEX NATIONAL PHARMACEUTICAL
JOINT STOCK COMPANY**

- Stock Code: MED

- Address: No. 358, Giai Phong Road, Phuong Liet Ward, Ha Noi City.

- Person responsible for information disclosure: Mr. Mai Nhat Thanh

Type of information disclosure: Periodic Extraordinary As required

2. Information Disclosure Contents:

- Notice of Amendment and Supplement to the Documents of the 2026 Annual General Meeting of Shareholders

3. This information was published on the company's website on June 17, 2026 at the link: <http://www.mediplantex.com/cổ-đông/công-bố-thông-tin>

We hereby commit that the information published above is accurate and are fully legally responsible for the content of the published information./.

**MEDIPLANTEX NATIONAL PHARMACEUTICAL
JOINT STOCK COMPANY**



Mai Nhat Thanh

MEETING INVITATION NOTICE

THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY

(This Meeting Invitation Notice replaces the previously issued Meeting Invitation Notice due to a change in the meeting schedule)

Dear: Shareholders of Mediplantex National Pharmaceutical Joint Stock Company

The Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company hereby respectfully announces and cordially invites shareholders to attend the 2026 Annual General Meeting of Shareholders (the “AGMS”) with the following details:

- 1. Time:** 1:30 p.m., Friday, June 29, 2026
- 2. Meeting Format:** The Meeting will be held online with electronic voting via the platform available at <https://med.ezgsm.fpts.com.vn/>.
- 3. Attendance Venue:** Shareholders or their duly authorized representatives may attend the Meeting online from any location of their choice, provided that they are able to access the online General Meeting platform and cast votes electronically at <https://med.ezgsm.fpts.com.vn/>.
- 4. Meeting Administration Venue:** No. 358 Giai Phong Road, Phuong Liet Ward, Hanoi, Vietnam.
- 5. Agenda:** The Meeting shall discuss and consider the approval of the following matters:
 - Report of the Board of Directors on its performance in 2025 and the proposed operational plan for 2026;
 - Report of the Board of Management on the 2025 business and production results and the implementation plan for 2026;
 - Report of the Board of Supervisors on its 2025 activities and supervisory work, along with the proposed plan for 2026;
 - Approval of the audited financial statements for the year 2025;
 - Selection of an independent auditing firm for the 2026 financial statements;
 - Approval of the profit distribution plan and dividend payout ratio for 2025, and the proposed profit distribution plan and dividend payout ratio for 2026;
 - Approval of the remuneration of the Board of Directors and the Board of Supervisors for 2025, and approval of the remuneration plan for 2026;
 - Approval of amendments and supplements to the Company's Charter on Organization and Operation;
 - Approval of the dismissal and election of an additional member of the Board of Directors for the 2024 – 2029 term;
 - Other matters within the authority of the General Meeting;
- 6. Participants:** All shareholders listed in the register of securities holders of Mediplantex National Pharmaceutical Joint Stock Company, as finalized by the Vietnam Securities Depository and Clearing Corporation on May 28, 2026, and individuals duly authorized by such shareholders, are eligible to attend the General Meeting.
- 7. Registration for Attendance and Voting:**
 - Shareholders attending the Meeting are requested to access <https://med.ezgsm.fpts.com.vn/> to register for attendance using the login credentials, including the Username and Password, provided in the Meeting Invitation Notice sent to each shareholder.

***Note:** Shareholders are responsible for maintaining the confidentiality of their login credentials to ensure that only authorized shareholders may attend and vote at the General Meeting of Shareholders. The Company shall not be liable for any issues arising from a shareholder's loss or disclosure of such login information.*

- Shareholders may exercise their voting rights at <https://med.ezgsm.fpts.com.vn/> under the “**Voting – Election**” section. The electronic voting system will be opened at least one (01) day prior to the official commencement of the Meeting, enabling shareholders and their authorized representatives to register attendance, vote, and participate in elections. The system will remain open until the Presidium announces the closure of the relevant voting agenda item or declares the adjournment of the Meeting
- In the case of authorization to attend the Meeting, shareholders are requested to prepare and submit the original Letter of Authorization to the address specified in Section 10 no later than **3:00 PM on June 24, 2026**, so that the Company may provide login credentials to the authorized representative. Alternatively, shareholders may register an authorization online through the system at <https://med.ezgsm.fpts.com.vn/> (the “**Authorization**” section.)
- The eligibility of shareholders or their authorized representatives to attend the Meeting shall be determined based on the shareholder records as of the record date provided by the Vietnam Securities Depository and Clearing Corporation (VSDC) and the authentication results from the online Meeting system. In the event of any dispute or complaint regarding attendance eligibility or voting rights, the Chairman of the Meeting shall have the authority to make a final decision based on the supporting documents provided by the parties and the applicable laws and regulations.

Note: A valid Letter of Authorization must be the original document, signed by both the authorizer and the authorized person, and stamped with the company seal in the case of institutional shareholders.

8. General Meeting Documents:

The meeting agenda and documents are fully uploaded and regularly updated on the website of Mediplantex National Pharmaceutical Joint Stock Company at: <https://www.mediplantex.com/>. Additionally, shareholders can view and download the meeting documents at the website: <https://med.ezgsm.fpts.com.vn/> (under the “**Documents**” section). Shareholders are kindly requested to review the documents in advance.

9. Other Matters:

To ensure the thorough preparation of the General Meeting, shareholders or groups of shareholders holding at least 5% of the Company’s total voting shares who wish to propose additions to the meeting agenda are kindly requested to submit their proposals in writing to the Company no later than **3:00 PM on June 24, 2026**.

In the event that shareholders do not receive the Meeting Invitation due to objective reasons, they shall still retain the right to attend the Annual General Meeting of Shareholders. Shareholders who have not received the Meeting Invitation are kindly requested to contact the Company for assistance if necessary.

10. Address for Document Submission and Support Contact:

MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY

No. 358 Giai Phong Street, Phuong Liet Ward, Hanoi

Phone: 024.38643363 / 091.611.7939 - Email: trang.chuh@mediplantex.com

Respectfully inviting esteemed shareholders to attend the meeting to ensure the success of the General Meeting.

Ha Noi, June 10, 2026

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRMAN**



Nguyen Ngoc Xuan Trang



**AGENDA OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY**

Time: 1:30 PM, Friday, Monday 29, 2026.

Venue: The General Meeting will be held online via electronic voting. Shareholders or authorized representatives can participate in the online General Meeting from any location with an Internet connection. The broadcasting hub for the Chairperson, the Presidium, and the Organizing Committee (the administrative venue) is located at: No. 358 Giai Phong Street, Phuong Liet Ward, Hanoi.

AGENDA

Time	Detailed Agenda	Execution
13h00 - 13h30	Instructions for Shareholders on Online Attendance and E-Voting	The Organizing Committee
	Report on Delegate Eligibility Verification	The Delegate Eligibility Committee
13h30 - 14h15	Opening of the meeting and introduction of delegates	The Organizing Committee
	Approval of the Meeting Agenda, Working and Voting-Election Regulations, and the Vote Counting Committee	
14h15 – 15h15 Reports & Proposals	Report of the Board of Directors on its performance in 2025 and the proposed operational plan for 2026.	Representative of the Board of Directors
	Report of the Board of Management on the 2025 business and production results and the implementation plan for 2026.	Representative of the Board of Management
	Report of the Board of Supervisors on the 2025 activities, supervisory work and the proposed plan for 2026.	Representative of the Board of Supervisors
	Proposal for the approval of the 2025 audited financial statements;	Representative of the Board of Directors
	Proposal for the selection of an independent auditing firm for the 2026 financial statements;	Representative of the Board of Supervisors
	Proposal for the approval of the profit distribution plan and dividend payout ratio for 2025, and the proposed profit distribution plan and dividend payout ratio for 2026;	Representative of the Board of Directors
	Proposal for the approval of remuneration for the Board of Directors and the Board of Supervisors for 2025 and the plan for 2026;	Representative of the Board of Directors
	Proposal for the approval of the amendments and supplements to the Charter on Organization and Operation of the Company;	Representative of the Board of Directors
	Approval of the Dismissal and Election for the Additional Members of the Board of Directors for the 2024–2029 Term	Representative of the Board of Directors
	Other matters within the authority of the General Meeting of Shareholders.	Representative of the Board of Directors
15h15 – 15h30	Discussion of the reports and proposals	Chairperson of the General Meeting
15h30 – 16h00	Conduct voting on the matters submitted to the General Meeting of Shareholders and elect an additional member to the Board of Directors for the 2024–2029 term	
16h00 – 16h15	Announcement of the voting and election results at the General Meeting of Shareholders	Ballot Counting Committee
16h15 – 16h35	Presentation of the draft Minutes and Resolutions of the Meeting	Secretariat
16h35 – 17h00	Approval of the Minutes and Resolutions of the Meeting	Chairperson of the General Meeting
	Conclusion and declaration of the Meeting's closure	



**MEDIPLANTEX NATIONAL
PHARMACEUTICAL JSC**

No. 01/2026/QĐ-HĐQT

THE SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

Hanoi, June , 2026

DECISION

**Regarding the Establishment of the Shareholder Eligibility Verification Committee
for the 2026 Annual General Meeting of Shareholders**

THE BOARD OF DIRECTORS OF MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY

- Pursuant to the Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam, on June 17, 2020, and effective as of January 1, 2021;
- Pursuant to the Charter on the organization and operation of Mediplantex National Pharmaceutical Joint Stock Company, as amended and supplemented for the 12th time on June 26, 2024;
- Based on the proposal of the General Director of the Company.

DECIDES

Article 1. To establish the Shareholder Eligibility Verification Committee to serve the 2026 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company, comprising the following members:

1. Ms. **Do Ngoc Thuy** – Head of the Committee
2. Ms. **Nguyen Thi Hoang Yen** – Member

The Shareholder Eligibility Verification Committee shall automatically dissolve upon completion of its assigned duties.

Article 2. The Committee is tasked with verifying the eligibility of shareholders attending the 2026 Annual General Meeting of Shareholders in accordance with applicable laws and the Company's Charter.

Article 3. This Decision takes effect from the date of signing. The General Director of Mediplantex National Pharmaceutical Joint Stock Company, the Head of the Organizing Committee of the 2026 Annual General Meeting of Shareholders, and the individuals named in Article 1 shall be responsible for implementing this Decision.

Recipients:

- BOD;
- As stated in Article 3;
- Archived: Office.

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRMAN**

Nguyen Ngoc Xuan Trang



**MEDIPLANTEX NATIONAL
PHARMACEUTICAL JSC**

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom – Happiness

No.: 02/TTr-HĐQT

Hanoi, June , 2026

DRAFT

PROPOSAL

**Regarding the Approval of the Vote Counting Committee
for the 2026 Annual General Meeting of Shareholders**

**To: The General Meeting of Shareholders of Mediplantex National Pharmaceutical
Joint Stock Company**

In order to carry out the counting of voting ballots and election ballots at the General Meeting of Shareholders, the Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company respectfully proposes to the General Meeting of Shareholders for approval the list of members of the Vote Counting Committee for the 2026 Annual General Meeting of Shareholders as follows:

List of Vote Counting Committee Members:

1. Ms. **Hoang Lan Huong** – Head of the Committee
2. Ms. **Duong Thi Minh Nguyet** – Member

Respectfully proposes to the General Meeting of Shareholders for consideration and approval./.

Recipients:

- As stated above;
- BOD, BOS;
- Archived: Office, BOD Office.

**ON BEHALF OF THE BOARD OF DIRECTORS
CHAIRMAN**

Nguyen Ngoc Xuan Trang



**JOINT STOCK COMPANY
MEDIPLANTEX CENTRAL
PHARMACY**

THE SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

Hanoi, June , 2026

DRAFT

**WORKING AND VOTING REGULATIONS
OF THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY**

Pursuant to:

- *The Law on Enterprise No. 59/2020/QH14 was passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, amended and supplemented by Law No. 03/2022/QH15 passed by the National Assembly of the Socialist Republic of Vietnam on January 11, 2022, and its implementing guidelines;*
- *The Law on Securities No. 54/2019/QH14, passed by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019, and its implementing guidelines; amended by Law No. 56/2024/QH15, passed by the National Assembly of the Socialist Republic of Vietnam on November 29, 2024, and its implementing guidelines.*
- *The Charter on Organization and Operation issued together with Resolution of the General Meeting of Shareholders No. 01/2024/NQ-GMS/MED dated June 26, 2024 of Mediplantex National Pharmaceutical Joint Stock Company;*
- *The Internal Regulations on Corporate Governance issued together with Resolution of the General Meeting of Shareholders No. 01/2024/NQ-GMS/MED dated June 26, 2024 of Mediplantex National Pharmaceutical Joint Stock Company.*

2026 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company (“MED”, “the Company”) was held and conducted in accordance with the following Working and Voting Regulations:

Article 1. Purpose

- To ensure that the procedures, principles of conduct, and voting at the Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company are carried out in accordance with regulations and in a successful and orderly manner.
- To ensure that the resolutions of the General Meeting of Shareholders reflect the unified will of the General Meeting, safeguard the legitimate rights and interests of

shareholders, and comply with applicable laws.

Article 2. Scope of Regulation and Subjects of Applicable

- **Scope of Regulation:** These Regulations shall apply to the organization of the 2025 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company.
- **Subjects of Application:** All delegates and authorized representatives attending the MED Annual General Meeting of Shareholders must comply with the provisions set forth in these Regulations, the Company's Charter, and the prevailing laws and regulations.

Article 3. Definitions

In these Regulations, the following terms are understood as follows:

1. **Shareholders:** are individuals who own at least one share of Mediplantex National Pharmaceutical Joint Stock Company and whose names are on the list of shareholders entitled to attend the General Meeting of Shareholders on May 28, 2026. Provided by the Vietnam Securities Depository and Clearing Corporation.
2. **The company or MED:** refers to Mediplantex National Pharmaceutical Joint Stock Company.
3. **Delegates are shareholders and/or their (valid) authorized representatives attending the 2026 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company.**
4. **Online General Meeting:** This is a form of organizing a shareholders' general meeting that uses electronic means to transmit images and sound via the internet, allowing shareholders in many different locations to attend the meeting, discuss, and vote on meeting issues.
5. **The online General Meeting venue** includes the main venue and other locations. The main venue is where the Chairperson attends and presides over the meeting, while the other locations are where shareholders log into the EzGSM System using their access accounts provided by MED to participate in the online General Meeting.
6. **Electronic voting:** This refers to shareholders casting votes and elections through the EzGSM system as stipulated in these Regulations.
7. **Electronic means:** are means that operate based on electrical, electronic, digital, magnetic, wireless transmission, optical, electromagnetic or similar technologies.

8. **Online registration for the General Meeting:** This refers to shareholders using their login information to access the system and register to attend the General Meeting online as stipulated in these Regulations and MED 's guidelines.
9. **Login Information:** This includes **the Username and Password** provided by MED to each shareholder in the Meeting Invitation Notice. Shareholders are responsible for keeping their login information and other identifying factors (if any) secure to ensure that only they have the right to use the login information to attend and vote on the system.
10. **Electronic voting system or online General Meeting of Shareholders system:** is a system that supports the organization of the General Meeting of Shareholders, providing delegates with tools to exercise their related rights when attending the General Meeting of Shareholders (including online delegate registration, proxy attendance, online voting and election, etc.);
11. **System Opening Time:** This is the time when shareholders can access, register to attend the online General Meeting, and vote on the items to be voted on at the meeting. The system will close access upon notification from the Chairman or the Organizing Committee of the General Meeting.
12. **Cumulative voting** is a method of cumulative voting where Delegates concentrate their votes on one (01) candidate or divide the votes equally among the maximum number of candidates according to the number of Board of Directors/Supervisory Board members to be elected; After dividing equally, the corresponding number of votes for each candidate is rounded down to the nearest whole number. Any remaining odd votes (if any) will be discarded;
13. **The total number of representative voting ballots** is understood to be the number of ballots with voting rights, including the number of ballots owned by a Delegate and/or authorized by one or more other Delegates;
14. **Total number of votes for board members** This is understood as the total number of representative voting ballots multiplied by the number of elected Board of Directors members.

In these Regulations, the following terms shall have the meanings set out below:

1. "Shareholder" means a person owning at least one share of Mediplantex National Pharmaceutical Joint Stock Company and whose name appears on the list of shareholders entitled to attend the General Meeting of Shareholders, finalized as of May 28, 2026 and provided by the Vietnam Securities Depository and Clearing Corporation (VSDC).

2. "Company" or "MED" means Mediplantex National Pharmaceutical Joint Stock Company.
3. "Delegate" means a shareholder and/or the duly authorized representative of a shareholder attending the 2026 Annual General Meeting of Shareholders of Mediplantex National Pharmaceutical Joint Stock Company.
4. "Virtual General Meeting" means a form of General Meeting of Shareholders conducted through electronic means for the transmission of images and audio via the Internet, enabling shareholders located in different places to attend the Meeting, discuss matters, and exercise their voting rights.
5. "Venue of the Virtual General Meeting" includes the principal venue and other venues. The principal venue is the location where the Chairperson attends and presides over the Meeting, while the other venues are locations where shareholders access the EzGSM System using the login credentials provided by MED in order to attend the Virtual General Meeting.
6. "Electronic Voting" means the exercise by shareholders of their voting rights and election rights through the EzGSM System in accordance with these Regulations.
7. "Electronic Means" means equipment, devices, or methods operating on electrical, electronic, digital, magnetic, wireless transmission, optical, electromagnetic, or similar technologies.
8. "Registration for Attendance at the Virtual General Meeting" means the use by a shareholder of the Login Credentials to access the system and register for attendance at the Virtual General Meeting in accordance with these Regulations and the instructions issued by MED.
9. "Login Credentials" include a Username and Password uniquely provided by MED to each shareholder in the Meeting Invitation Notice. Shareholders are responsible for maintaining the confidentiality of their Login Credentials and any other identification factors (if any) to ensure that only the shareholder is entitled to use such credentials to attend and vote through the system.
10. "Electronic Voting System" or "Online General Meeting System" means the system supporting the organization of the General Meeting of Shareholders and providing Delegates with tools to exercise their rights in connection with attendance at the General Meeting of Shareholders, including online registration, proxy appointment, electronic voting, and online election procedures.
11. "System Opening Time" means the time from which shareholders may access the system, register for attendance at the Virtual General Meeting, and vote on matters submitted for approval at the Meeting. Access to the system shall be closed in

accordance with the announcement of the Chairperson or the Organizing Committee of the Meeting.

12. "Equal Distribution of Cumulative Votes" means a method of cumulative voting whereby Delegates may allocate all of their votes to one (01) candidate or distribute their votes equally among a number of candidates not exceeding the number of members of the Board of Directors or the Supervisory Board to be elected. Following such distribution, the number of votes allocated to each candidate shall be rounded down to the nearest whole number. Any remaining fractional votes shall be disregarded.
13. "Total Number of Represented Voting Rights" means the total number of voting rights represented by a Delegate, including voting rights attached to shares owned by the Delegate and/or voting rights validly authorized by one or more other Delegates.
14. "Total Number of Votes for the Election of Members of the Board of Directors" means the Total Number of Represented Voting Rights multiplied by (x) the number of members of the Board of Directors to be elected.

Article 4. Conditions and procedures for conducting the General Meeting of Shareholders (*According to the Company's Charter*)

1. The General Meeting of Shareholders (GMS) shall be convened when the attending shareholders represent more than 50% of the total voting shares.
2. In the event that the required number of shareholders is not present within thirty (30) minutes from the scheduled opening time of the meeting, a second meeting invitation must be issued within thirty (30) days from the intended date of the first GMS. The reconvened GMS shall only be conducted if the attending shareholders and authorized representatives represent at least 33% of the total voting shares.
3. If the second meeting cannot be held due to the absence of the required number of attendees within thirty (30) minutes from the scheduled start, a third meeting invitation must be issued within twenty (20) days from the intended date of the second GMS. In this case, the GMS shall be convened regardless of the number of shareholders or authorized representatives in attendance and shall be deemed valid, with the authority to decide on all matters originally proposed for approval at the first GMS.
4. The system for organizing online meeting and electronic voting must meet the following conditions:
 - The system must be maintained to operate safely and stably, ready to meet the connectivity and participation requirements of shareholders.
 - The main venue must ensure adequate sound, lighting, internet connection, power

supply, electronic equipment, and other facilities as required by the nature of the online meeting.

- Ensure information security and maintain the confidentiality of access accounts to the System. All information received and provided on the System must adhere to information security principles and comply with the regulations of the Law on Cybersecurity.
- Electronic data from the online conference program must be recorded, stored, and used in accordance with regulations.

Article 5. Registration for Attendance at the Online General Meeting of Shareholders

1. Participants:

Shareholders of MED holding voting shares (according to the list of shareholders finalized on the record date of May 28, 2026) shall have the right to attend the General Meeting of Shareholders in person or authorize their representatives to attend on their behalf. Where a shareholder is an individual, he/she may authorize only one other individual to attend the Meeting on his/her behalf. Where a shareholder is an organization entitled under applicable laws to appoint more than one authorized representative to attend the Meeting, the number of shares and voting rights represented by each authorized representative must be clearly specified. An authorized representative who has been authorized to attend the Meeting may not further delegate such authority to a third party.

2. Technology requirements:

Delegates shall attend the Online General Meeting of Shareholders and conduct electronic voting through the website: med.ezgsm.fpts.com.vn. Delegates attending the Online General Meeting of Shareholders must have an electronic device with Internet access to ensure their ability to follow the proceedings of the Meeting and participate in electronic voting, including but not limited to computers, mobile phones, tablets, and other Internet-enabled electronic devices.

3. Method of Attendance:

- For shareholders:

Each shareholder listed in the register of shareholders entitled to attend the 2026 Annual General Meeting of Shareholders as of May 28, 2026 shall be provided with one (01) unique username and one (01) corresponding password for access to the General Meeting and participation in electronic voting.

Such username and password shall be provided to each shareholder together with the Notice of Invitation to the General Meeting of Shareholders. Upon receipt of the Notice containing information relating to the access account, shareholders shall be responsible for maintaining the confidentiality of such information to ensure that only the shareholder may access and vote through the Electronic Voting System.

The Company recommends that, upon receipt of the login credentials, including at minimum the username and password, shareholders promptly access the system and change their password in order to enhance account security.

A shareholder who registers to attend the Online General Meeting after the Meeting has officially commenced may still register and shall be entitled to vote and participate in elections upon completion of the registration process. The Chairperson shall not be required to suspend the Meeting, and the validity of any voting conducted prior to such registration shall remain unaffected.

- For authorized representatives of shareholders:

Shareholders and authorized representatives of organizational shareholders may attend the Meeting directly or authorize one or more individuals or organizations to attend the Online General Meeting and participate in electronic voting on their behalf.

Such authorization must be made in writing. The power of attorney shall be prepared in accordance with applicable civil laws and must clearly specify the name of the authorizing shareholder; the name of the authorized individual or organization; the number of shares represented; the scope and content of authorization; the term of authorization; and the signatures of both the authorizing party and the authorized party.

The individual or organization authorized to attend the General Meeting of Shareholders must submit the original valid power of attorney to the Company no later than 3:00 p.m. on June 24, 2026 so that the Company may provide login credentials for access to the Online General Meeting System.

Where the authorized representative is not a shareholder of MED, upon receipt of a duly executed authorization document from both the authorizing party and the authorized party, MED shall provide a username and password to the authorized representative, enabling him/her to exercise the rights and perform the obligations delegated under the authorization.

Mediplantex National Pharmaceutical Joint Stock Company shall provide login credentials to the authorized representative via email or by other means based on the registration information provided by the shareholder. The shareholder shall bear full

responsibility for the authorization information submitted to MED.

Where the authorized representative is also a shareholder of the Company, such representative shall use his/her own access account (as stated in the Company's Notice of Invitation) to attend the Meeting and exercise the voting rights authorized by the shareholder at the General Meeting of Shareholders.

- **Revocation of Authorization:**

A shareholder may revoke an authorization by submitting an official written notice of revocation to the Company prior to the official commencement of the Meeting.

The effective time of such revocation shall be determined based on the time at which the Company receives the written notice of revocation.

A revocation of authorization shall not be effective if the authorized representative has successfully completed online attendance registration through the Electronic Voting System in accordance with Article 6 of these Regulations or has already cast a vote on any matter included in the agenda of the General Meeting of Shareholders.

4. Reissuance of Login Credentials.

Where a shareholder requests the reissuance of login credentials, the Organizing Committee may require the shareholder to provide personal identification information, including at a minimum: For individual shareholders: Citizen Identification Card/Passport number, mobile phone number, email address, and permanent or temporary residential address (or correspondence address); For organizational shareholders: Enterprise Registration Certificate number, contact telephone number, and registered head office address. The Company may resend the username and password to the shareholder via email or by other means based on the registration information provided by the shareholder, enabling the shareholder to attend and vote at the Meeting..

Article 6. Method of recording the attendance of delegates at the online General Meeting of Shareholders

1. Delegates are considered to have attended the General Meeting online from the moment they successfully register to attend the meeting online through the Electronic Voting System, as per the Guidelines for Attending the 2026 Annual General Meeting of Shareholders posted on the Company's website.
2. Delegates are considered to have participated in the online Congress validly and fully when they do so in one of the following ways:
 - Attending the Online Congress: I have logged in and registered to attend the meeting

on the online congress system via the following link : med.ezgsm.fpts.com.vn , using the username and password provided by the Company during the General Meeting until the end of the voting period.

- In the event that a delegate has logged in and registered to attend but does not vote by the time of voting, the shareholder will still be considered to have attended the General Meeting and will be deemed to have not voted, in accordance with the procedures, content of the meeting, voting results, and meeting minutes.

Article 7. Rights and obligations of delegates when attending the online General Meeting of Shareholders

1. Attend the General Meeting online and vote on all matters of the General Meeting as stipulated in the Charter of Organization and Operation of Mediplantex National Pharmaceutical Joint Stock Company, this Regulation, and the guidelines on the company's website.
2. Have the right to express their opinions and participate in discussions at the Congress as stipulated in Article 12 of these Regulations.
3. Comply with the instructions of the Chairperson and refrain from causing disruption or disorder during the Congress.
4. Delegates must prepare and use appropriate online meeting equipment with an internet connection to ensure they can follow the proceedings of the online Congress.
5. All electronic voting results of delegates are considered to reflect the will of the delegates. Voting results obtained electronically have the same legal validity as voting at a face-to-face congress.
6. Delegates may use the login information provided by MED to access, participate in, and electronically vote on all voting and election matters of the Congress. Delegates are responsible and have no right to complain if they leave the system for any reason or allow others to use their login information to access the system during the Congress, from the time the system opens for registration, discussion, and voting until it closes.
7. Delegates are responsible for keeping their login information secure to ensure that only shareholders have the right to attend and vote electronically on the system. The company will provide maximum support in ensuring delegates can attend and vote at the General Meeting of Shareholders, but will not be responsible for any issues arising from shareholders losing their login information. In the case of proxy attendance, both the shareholder and the authorized person are responsible for the authorization and the results of electronic voting based on the provided login information.

8. In cases where delegates, after registering to attend the online General Meeting, are unable to participate continuously until the end of the program, they may vote on matters requiring shareholder approval before logging out of the system.

Article 8. Chairperson

1. The Chairman of the Board of Directors or a member of the Board of Directors authorized by the Chairman of the Board of Directors shall be the Chairperson of the 2026 Annual General Meeting of Shareholders of MED.
2. In case the Chairperson is absent or temporarily unable to perform duties, the remaining members shall elect one among themselves to act as the Chairperson of the meeting according to the majority rule. In the event that no Chairperson is elected, the Head of the Board of Supervisors shall preside over the process for the General Meeting of Shareholders to elect a Chairperson of the meeting, and the person who receives the highest number of votes shall act as the Chairperson of the meeting
3. Duties of the Chairperson:
 - a. To preside over the activities of the General Meeting of Shareholders in accordance with the Agenda proposed by the Board of Directors and approved by the General Meeting;
 - b. To guide the Delegates and the Meeting in discussing the matters included in the agenda;
 - c. To present draft resolutions and provide conclusions on necessary issues for the General Meeting to vote on;
 - d. To respond to matters requested by the General Meeting;
 - e. To address any issues arising during the course of the Meeting.

Article 9. Secretariat of the General Meeting

1. The Secretariat of the General Meeting is nominated by the Chairperson (through the General Meeting Organizing Committee); is responsible to the Chairperson and the General Meeting of Shareholders for their duties and operate under the direction of the Chairperson.
2. The Secretariat's responsibilities:
 - a. Assist the Chairperson in verifying the credentials of delegates attending the meeting (when necessary);
 - b. Assist the Chairperson in announcing draft documents, conclusions, and resolutions

of the Congress, and send notifications from the Chairperson to delegates when requested;

- c. Compile the opinions of shareholders during the online General Meeting and submit them to the Chairperson;
- d. Record fully and truthfully the entire content and proceedings of the Congress, as well as the issues that were approved or are still being considered, in the Congress Minutes;
- e. Prepare meeting minutes and draft resolutions on issues adopted at the Congress;
- f. Assist the Chairperson in announcing information related to the General Meeting of Shareholders and notifying the Shareholders' Delegates in accordance with legal regulations and the Company's Articles of Association.

Article 10. Delegate Eligibility Verification Committee

1. The Delegate Eligibility Verification Committee of the General Meeting shall consist of two (02) members, including one (01) Head of the Committee and one (01) member. The Committee shall be established by the Board of Directors and introduced to the General Meeting by the Chairperson. The Delegate Eligibility Verification Committee shall be accountable to the Chairperson and the General Meeting of Shareholders for the performance of its duties.
2. Duties of the Delegate Eligibility Verification Committee:
 - a. To examine and verify the eligibility of Delegates registering to attend the Online General Meeting in accordance with applicable laws, the Company's Charter on Organization and Operation, and these Regulations.
 - b. To report to the Online General Meeting on the percentage of attending Delegates. The Delegate Eligibility Verification Committee shall rely on the login information associated with the Delegates' access accounts as the basis for determining attendance at the Online General Meeting.
 - c. If the Meeting is attended by Delegates representing more than fifty percent (50%) of the total voting shares, the General Meeting of Shareholders of MED shall be duly convened and entitled to proceed.

Article 11. Vote Counting Committee

1. The Vote Counting Committee of the General Meeting shall consist of 02 members, including 01 Head and 01 members, who are nominated by the Chairperson (through the Meeting Organizing Committee) and approved by the General Meeting.

2. Duties of the Vote Counting Committee:
 - a. Disseminate the principles, regulations, and guidelines on the voting procedures;
 - b. Verify and record voting cards, prepare vote counting minutes, announce results; submit the minutes to the Chairperson for approval of voting and election results;
 - c. Promptly notify the Meeting Secretary of the voting results;
 - d. Review and report to the General Meeting any violations of voting regulations or complaints regarding the voting results;
 - e. Prepare the vote counting minutes and be accountable to the Chairperson and the General Meeting of Shareholders in the performance of their duties.

Article 12. Discussion at the General Meeting

1. Principle:
 - a. Discussions will only be conducted within the stipulated time and will be limited to the issues presented in the agenda of the Shareholders' General Meeting;
 - b. Shareholders conduct discussions as instructed by the Chairperson during the online General Meeting;
 - c. Shareholders can participate in discussions at the online General Meeting by submitting their opinions through the direct connection methods guided by the company on the company website. The Secretariat is responsible for compiling the shareholders' opinions and sending them to the Presiding Board, while also recording the shareholder's name, shareholder code (if any), and the content of the question;
2. Responding to the delegates' questions:
 - a. Based on the discussion comments submitted by the delegates, the Chairperson or a member designated by the Chairperson will address the delegates' comments.
 - b. In case of time constraints, questions that were not answered directly at the General Meeting will be answered by the company to shareholders through appropriate means.

Article 13. Voting on Matters Submitted to the General Meeting

1. Voting period

- a. Shareholders may cast their votes from the time the voting function becomes active on the System (at least one (01) day prior to the official opening of the General Meeting) until the voting period is declared closed by the Chairperson of the Meeting. Where a shareholder has already cast a vote but wishes to change his/her voting decision, such change must be made before the voting period closes. The last

voting instruction recorded by the System before the closing of the voting period shall be deemed valid and shall be included in the vote-counting results.

- b. Prior to the closing of the voting period, shareholders may only view their own voting results. Upon the closing of the voting period, the overall voting results for each agenda item shall be announced by the Chairperson or the Vote Counting Committee.

2. Voting method

- a. Shareholders shall use the Login Information provided by the Company in the Notice of Invitation to access the System at <https://med.ezgsm.fts.com.vn> in accordance with the instructions published on the Company's website at <https://www.mediplantex.com> and cast their votes electronically
- b. For each matter submitted for approval, a Delegate shall select one (01) of the following voting options: “**Approve**”, “**Disapprove**”, or “**Abstain**”, and then click the “**Vote**” button to save and submit the voting result to the System. Before the voting period closes, a Delegate may change his/her voting decision by selecting another voting option and clicking the “**Change Vote**” button to confirm the final voting instruction. If a Delegate fails to click the confirmation button to submit the vote through the Electronic Voting System before the voting period closes, such voting card shall be deemed not returned in respect of the relevant agenda item. Where a Delegate does not select any voting option, such Delegate shall be deemed to have declined to exercise his/her voting right and not to have participated in voting on that matter. The corresponding voting rights shall not be included in the total number of votes participating in the voting for that matter.
- c. Depending on the proceedings and agenda of the General Meeting, voting on matters submitted to the General Meeting may be conducted in multiple voting rounds. Shareholders attending the Online General Meeting shall comply with the voting period applicable to each voting round as announced by the Chairperson and notified through the Electronic Voting System. Shareholders shall cast votes on all matters included in the same voting round.
- d. An invalid voting card is a voting card containing one or more agenda items on which no voting opinion has been indicated by the Delegate. The Electronic Voting System shall issue a warning in the event of an invalid voting card. Shareholders shall be responsible for correcting and resubmitting a valid voting card. Invalid voting cards

shall not be recorded by the System, and the relevant shareholder shall be deemed present but not to have voted on the relevant matter (i.e., a non-returned vote).

- e. A Delegate may change his/her voting result multiple times but may not revoke a vote once cast. The Electronic Voting System shall only recognize the final voting instruction recorded at the time the voting period closes for each voting round as determined by the Chairperson. The voting results for each agenda item shall be reported to the General Meeting by the Vote Counting Committee immediately after completion of the vote-counting process.
- f. During the conduct of the General Meeting, the Chairperson shall announce the closing time of voting on the System so that shareholders may exercise their rights accordingly. Where a shareholder encounters technical difficulties in casting votes through the System, such shareholder may contact the hotline announced by the Organizing Committee for guidance and assistance. Upon closure of voting for a particular matter on the System, shareholders shall no longer be entitled to cast votes or modify any voting instruction relating to that matter. The voting results recorded by the System based on the shareholder's Login Credentials shall be deemed final and conclusive, and no complaint, dispute, or legal action relating thereto shall be accepted.

3. Voting rules:

- a. Each share owned or represented shall carry one (01) vote.
- b. Pursuant to Clause 1, Article 21 of the Company's Charter, resolutions on the following matters shall be approved if they receive affirmative votes representing at least sixty-five percent (65%) of the total voting rights of all shareholders attending and voting at the General Meeting:
 - Amendments and supplements to the Company's Charter;
 - Types of shares and the total number of shares to be offered for sale;
 - Merger, reorganization, or dissolution of the Company;
 - Investments or transactions involving the sale of assets with a value equal to or exceeding thirty-five percent (35%) of the total assets recorded in the Company's most recently audited financial statements;
 - Changes to the Company's business lines, industries, or business sectors.
- c. Except for the matters specified above, all other resolutions shall be approved if they receive affirmative votes representing more than fifty percent (50%) of the total voting rights of all shareholders attending and voting at the General Meeting, except in cases

otherwise provided for in Clause 1, Article 21 of the Company's Charter and Clauses 3, 4, and 6 of Article 148 of the Law on Enterprises.

4. Vote Counting Method and Voting Results

- a. The vote counting committee, approved by the General Meeting of Shareholders, is responsible for verifying the results of the electronic voting to compile the final voting results.
- b. The electronic voting system records the number of ballots issued, the number of ballots received, the number of ballots not received, and the percentage of the total votes cast by all shareholders attending and voting at the meeting.
- c. All ballots received and recorded by the electronic voting system are valid.
- d. Each delegate's vote is recorded by the system as follows: the number of votes in favor, the number of votes against, and the number of abstentions.
- e. The voting results are announced by the Chairperson or the Vote Counting Committee immediately at the online Congress.

Article 15. Election of additional members to the Board of Directors

1. Election method:

The voting for the election of additional members to the Board of Directors for the 2024-2029 term will be conducted using the cumulative voting method. Accordingly:

- Each delegate has a total number of votes corresponding to the total number of shares they represent multiplied by the number of additional members elected to the Board of Directors for the 2024-2029 term.
- Delegates may allocate all or part of their total votes to one or more individuals, but not exceeding the number of members approved by the General Meeting of Shareholders.
- The elected members of the Board of Directors are determined by the number of votes received, from highest to lowest, starting with the candidate with the highest number of votes until the required number of members is elected. If two or more candidates receive the same number of votes, a re-election will be held among those candidates, or a selection will be made based on other criteria approved by the General Meeting of Shareholders.

2. Election Ballot:

Each ballot for the election of members of the Board of Directors may be used to elect up to the maximum number of Board members to be elected, as approved by the General Meeting of Shareholders.

Each ballot for electing board members has two columns: "Cumulative voting" and "Number of votes". Shareholders should cast their votes according to the following instructions:

Case 1: If the Delegate casts all their votes for one person (01) candidate

Delegates should check the box in the "Allocate votes equally" column for the respective selected candidates.

Case 2: If the delegate does not vote for any candidate.

Delegates should leave the "Equally Selected" and "Number of Votes" columns blank, **and NOT** mark any symbols for all candidates.

3. Online Election Procedure:

The election voting period shall commence when the Electronic Voting System is activated and shall continue until the Chairperson of the General Meeting or the Vote Counting Committee announces the close of the election voting period. Delegates who exercise their voting rights from the time the Electronic Voting System is activated shall be counted as attending the Online General Meeting of Shareholders.

After completing the election ballot, the Delegate shall click the "Vote" button to save and submit the election results to the System. Delegates may amend their election votes at any time before the close of the election voting period as directed by the Chairperson; however, they may not withdraw their election votes. The election results recorded by the System at the close of the voting period shall be deemed the final and valid election results of the Delegate. Upon the expiration of the election voting period, the System shall no longer accept or record any additional electronic election votes submitted by Delegates.

4. Validity of ballots

For invalid ballots, the electronic voting system will send a warning to delegates attending the online General Meeting of Shareholders and those who cast their votes electronically. Delegates are responsible for correcting their ballots to make them valid. The system will not record invalid ballots, and delegates will be considered as not having participated in the election through the electronic voting system.

Article 16. Minutes of Meeting, Resolutions of the General Meeting of Shareholders

The minutes and resolutions of the General Meeting of Shareholders must be read and approved before the closing of the meeting.

Article 17. Implementation of the Regulations

Delegates and guests attending the General Meeting must strictly comply with these Working and Voting Regulations, the company's current regulations, internal rules, and governance regulations, and relevant legal provisions. Delegates who violate these Rules will be subject to disciplinary action by the Chairperson, depending on the severity of the violation, in accordance with the Company Charter and the Law on Enterprises.

These regulations consist of 17 articles and will take effect immediately after being approved by the Company's 2026 Annual General Meeting of Shareholders.

**OB. BOARD OF DIRECTORS
CHAIRMAN**

Nguyen Ngoc Xuan Trang

T.C.P

No: 03/2026/BC-MED

Hanoi, June , 2025

DRAFT

**REPORT OF THE BOARD OF SUPERVISORS
ON THE 2025 ACTIVITIES, SUPERVISORY WORK AND THE
PROPOSED PLAN FOR 2026**

To: The General Meeting of Shareholders



- Pursuant to the Law on Enterprises and the Charter of MediPlantex National Pharmaceutical Joint Stock Company stipulating the functions and authority of the Board of Supervisors;

- Pursuant to the Resolution of the 2024 General Meeting of Shareholders and the Resolutions of the Board of Directors in 2024;

- Pursuant to the business performance results and the audited 2025 financial statements;

The Board of Supervisors (BOS) of MediPlantex National Pharmaceutical Joint Stock Company respectfully submits to the Annual General Meeting of Shareholders (GMS) the report on its activities in 2025 and the proposed plan for 2026, with the following key contents:

I. Organization and Activities of the Board of Supervisors:

1. Personnel of the Board of Supervisors:

The Board of Supervisors consists of 3 members, including:

- Mr. Ho Ngoc Tuan : Head of the Board of Supervisors
- Ms. Ha Thi Bich Hanh : Member of the Board of Supervisors
- Ms. Do Ngoc Thuy : Member of the Board of Supervisors

2. Activities of the Board of Supervisors:

During the year, the Board of Supervisors fully performed its duties and responsibilities as assigned by the General Meeting of Shareholders, specifically overseeing, inspecting, and supervising the Company's governance, management, and business operations. The Board operated with a strong sense of responsibility, clearly delegated tasks to each member, and appointed representatives to attend meetings of the Board of Directors (BOD) and the Board of Management (BOM).

The Board of Supervisors maintained close and regular working relations with the BOD and the General Director in business operations, monitoring the Company's

activities to ensure compliance with applicable laws, exchanged information with the BOD and General Director regarding the implementation of business plans and resolutions approved by the General Meeting of Shareholders.

Based on its functions and duties as stipulated by the Law on Enterprises, the Company's Charter, and the Regulations on Organization and Operation of the Board of Supervisors, the Board carried out the following activities during the year:

- Attended the Company's Annual General Meeting of Shareholders.
- Participated in regular and extraordinary meetings of the Board of Directors.
- Monitored financial and accounting activities, including review of the semi-annual and annual financial statements of the Company.
- Supervised the activities of the BOD and the Board of Management in accordance with the law and resolutions of the General Meeting of Shareholders.
- Oversaw the Company's information disclosure in compliance with legal regulations.
- Proposed the selection of an independent auditing firm to audit the Company's annual and semi-annual financial statements; assessed the financial statements before and after the audit.
- Provided input on the development of operating regulations for the Company by the BOD and the Board of Management.
- Cooperated with relevant departments to inspect and assess business operations.
- Held regular and extraordinary meetings of the Board of Supervisors to review, discuss, and evaluate the Company's performance, in which:
 - + A meeting to review the Supervisory Board's performance in 2025 and approve its operational plan for 2026.
 - + A meeting to consider and recommend the appointment of an independent audit firm to audit the Company's 2026 financial statements for submission to the Annual General Meeting of Shareholders for approval.
 - + A meeting to review the independent auditor's report for the financial year ended 31 December 2025.
- Performed other duties in accordance with the functions and responsibilities of the Board of Supervisors.

3. Remuneration, Salaries and Other Benefits of the Members of the Supervisory Board

During 2025, the remuneration, salaries and other benefits paid to the members of the Supervisory Board are presented in the audited Financial Statements for the year ended 31 December 2025.

II. Evaluation by Task Group:

1. Evaluation by the BOS on the Activities of the BOD:

- Governance activities were carried out in accordance with the law, the Company's Charter, and the resolutions of the General Meeting of Shareholders.

- The BOD ensured transparency and openness in management, with a strategic focus on business development and efficiency.

- The BOD held regular meetings with clear agendas, documented minutes, and issued resolutions instructing the General Director to implement decisions. However, in the past period, the BOD was unable to organize meetings as regularly planned due to the health condition of the Chairman. The BOS recommends that the BOD resume regular meetings as prescribed.

- During the year, the BOD amended, supplemented, and issued several regulations, documents, resolutions, and decisions, providing a structured, focused, and unified foundation for corporate governance.

2. Evaluation by the BOS on the General Director's Implementation of Resolutions of the GMS and the BOD:

- The General Director implemented various measures to strengthen financial management by controlling expenses, monitoring customer receivables, and managing operational activities in line with the objectives set by the General Meeting of Shareholders and the BOD.

- Took the initiative in executing the business plan, fully fulfilled obligations to the State and shareholders, and paid attention to employee welfare.

- Organized the year-end review conference to comprehensively evaluate business operations, identify limitations and shortcomings, and propose appropriate solutions and corrective actions.

- Focused on addressing internal weaknesses of the Company to improve operational efficiency and reduce costs.

- Regarding investment and co-investment projects that are behind schedule, the Board of Supervisors submitted recommendations to the BOD and the Board of

010
ĐNG
PHI
TRUNG
PLAN
AJP
10 H

Management, requesting a thorough review to ensure legal compliance and investment efficiency.

- For several resolutions issued by the BOD that have not yet been implemented, the Board of Supervisors recommends that the BOM promptly report back to the BOD on the reasons for the delay and the implementation progress.

III. Review and Evaluation of Financial Statements:

1. Preparation and Audit of Financial Statements:

- The Company's financial statements were prepared in accordance with current Vietnamese Accounting Standards. The annual and semi-annual financial statements were audited by AASC Auditing Firm Company Limited.

- The Board of Supervisors reviewed the financial statements and concurred with the reported business results. According to the audit opinion provided by AASC, the Company's financial statements were presented fairly, accurately, completely, and clearly, and were in compliance with applicable accounting standards.

However, the auditing firm issued a qualified opinion on the Company's 2025 audited financial statements, not an unqualified opinion, due to a limitation in the audit scope related to two business cooperation contracts: Contract No. 68/HDHTKD dated June 1, 2017 (cooperation in developing the project at the land lot located at 190 Dinh Thon Street, My Dinh 1 Ward, Nam Tu Liem District) and Contract No. 35/2009/HĐHT dated December 25, 2009 (cooperation in developing the project at the land lot located at 118 Nguyen Van Troi Street, Phuong Liet Ward, Thanh Xuan District). As the Company is currently working with its partners and relevant authorities on the implementation of these contracts, the information has not yet been provided to the auditors.

Regarding this matter, the Board of Supervisors has required that the Company engage a consulting firm to promptly resolve the issue and protect the Company's rights and interests in accordance with regulations. In addition, the Board of Supervisors has submitted its recommendations on this matter to the BOD and BOM, and requested that the BOD and BOM take appropriate action and implement necessary solutions.

2. Business Performance Results:

The Company closely followed the business targets set by the GMS and focused on implementing solutions to enhance production capacity, improve product quality, reduce costs, and increase operational efficiency.

IV. Recommendations for the Board of Directors and the General Director to continue addressing in the coming period:

- The BOD should consider developing a long-term business strategy to enhance proactiveness in operations.

- Improve and strengthen training and recruitment of qualified and experienced staff, as well as highly skilled technical workers, to support future business and production activities.

- Continue implementing more effective measures to recover due receivables and bad debts.

- Accelerate the implementation of the Pharmaceutical Science and Technology Center and the EU-GMP-standard Pharmaceutical Manufacturing Plant Project to bring it into efficient operation as soon as possible.

V. Report on Transactions between the Company and Members of the Board of Directors, the General Director, other executive officers, and their related persons; and transactions between the Company and companies in which members of the Board of Directors, the General Director, or other executive officers are founders or managers within the last three (03) years prior to the transaction date

In 2025, all transactions between the Company and related parties were submitted to and approved by the Board of Directors in accordance with proper procedures and were fully compliant with disclosure obligations. Details of related-party transactions are presented in the audited Financial Statements for 2025 and the Company's Corporate Governance Report. The Board of Supervisors confirms that the transaction procedures complied with regulations, with no violations detected. The transactions were conducted in a transparent manner, ensuring effective control of conflicts of interest and safeguarding the interests of the Company and its shareholders.

VI. Work Plan of the Board of Supervisors for 2026:

- Perform inspection and supervision duties over the governance and management activities of the Board of Directors and the Board of Management in accordance with the Company's Charter and the Law on Enterprises;

- Monitor the implementation of resolutions of the General Meeting of Shareholders and resolutions of the Board of Directors in the course of business operations, based on legal regulations and the Company's Charter;

- Review the appropriateness of internal documents and management regulations and their practical application to ensure alignment with the resolutions of the General Meeting of Shareholders. Propose amendments or supplements to internal regulations if deemed necessary;

- Examine accounting records, vouchers, and other Company documents when necessary or upon request of the General Meeting of Shareholders;
- Propose the selection of an independent auditing firm to audit the Company's semi-annual and annual financial statements;
- Review and evaluate financial statements and the Company's business performance on a quarterly, semi-annual, and annual basis;
- Maintain close coordination between the Board of Supervisors, the Board of Directors, the Board of Management, and other relevant units within the Company;
- Participate in major Company activities to stay informed about business operations;
- Attend BOD meetings and quarterly briefings to stay up to date on the Company's situation.

VII. General Assessment of the Activities of the Board of Supervisors:

- The Board of Supervisors performed its functions and duties in accordance with the Company's Charter and the relevant provisions of the Law on Enterprises relating to the Board of Supervisors.
- The Board of Supervisors fulfilled the responsibilities entrusted to it by shareholders, particularly in overseeing business operations and the effective use of capital.
- The performance of the Board of Supervisors during the term was the result of the efforts of each member, as well as the trust, support, and facilitation provided by the Board of Directors, the General Director, departments, and all employees of the Company.

On behalf of the Board of Supervisors, I would like to sincerely thank the General Meeting of Shareholders, the Board of Directors, and the General Director for their trust, support, and cooperation throughout the past year, which enabled the Board of Supervisors to fulfill its duties effectively.

Respectfully!

Recipient:

- Shareholders;
- BOD; BOM;
- BOS;
- Archived: BOS; Secretary; Office.

**ON BEHALF OF THE BOARD OF SUPERVISORS
HEAD OF THE BOARD**

Ho Ngoc Tuan



MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY
2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS

VOTING BALLOT
DELEGATE ID:



Full name:

Number of votes owned:..... votes

Number of votes authorized:..... votes

Total number of votes represented:votes

(Check the corresponding box for your choice in each content)

CONTENT	Approve	Disapprove	Abstain
Content 01: Agenda of the 2026 Annual General Meeting of Shareholders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 02: Working and Voting Regulations of the 2026 Annual General Meeting of Shareholders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 03: The Vote Counting Committee for the 2026 Annual General Meeting of Shareholders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Guide:

Shareholders tick (X) in one of 3 boxes:

Approve/Disapprove/Abstain each Content.

June 29th 2026

DELEGATE

(Signature and full name)

**MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY
2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS**



**VOTING BALLOT
DELEGATE ID:**

Full name:

Number of votes owned: votes

Number of votes authorized: votes

Total number of votes represented:votes

(Check the corresponding box for your choice in each content)

CONTENT	Approve	Disapprove	Abstain
Content 01: Report of the Board of Directors on 2025 performance results and the implementation plan for 2026 activities	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 02: Report of the Board of Management on the 2025 business and production results and the implementation plan for 2026	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 03: Report of the Board of Supervisors on the 2025 activities, supervisory work and the proposed plan for 2026	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 04: Approval of the 2025 Audited Financial Statements	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 05: Approval of the Selection of the Independent auditing firm for the 2025 Financial Statements	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 06: Approval of the profit distribution plan and dividend payout ratio for 2025, and the proposed profit distribution plan and dividend payout ratio for 2026	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 07: Approval of remuneration report for the Board of Directors, Board of Supervisors for 2025 and the plan for 2026	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 08: Approval of the Amendments and Supplements to the Charter on Organization and Operation of the Company	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 09: Approval of the Dismissal and Election for the Additional Members of the Board of Directors for the 2024 – 2029 Term	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Guide:

Shareholders tick (X) in one of 3 boxes:

Approve/Disapprove/Abstain each Content.

June 29th 2026

DELEGATE

(Signature and full name)

MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY
2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS



VOTING BALLOT
DELEGATE ID:

Full name:

Number of votes owned: votes

Number of votes authorized: votes

Total number of votes represented:votes

(Check the corresponding box for your choice in each content)

CONTENT	Approve	Disapprove	Abstain
Content 01: Resolution of the 2026 Annual General Meeting of Shareholders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Content 02: Meeting Minutes of the 2026 Annual General Meeting of Shareholders	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Guide:

Shareholders tick (X) in one of 3 boxes:

Approve/Disapprove/Abstain each Content.

June 29th 2026

DELEGATE

(Signature and full name)

MEDIPLANTEX NATIONAL PHARMACEUTICAL JOINT STOCK COMPANY
2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS



VOTE ON THE BOARD OF DIRECTORS
DELEGATE ID:

Full name:

Number of votes owned:..... votes

Number of votes authorized:..... votes

Total number of votes represented:votes

Total number of voting rights voting rights

I hereby agree to cast the votes for the chosen Additional Member of the Board of Directors

No	Full Name	Cumulative voting	Number of votes
1	...	<input type="checkbox"/>	<input type="text"/>
2	...	<input type="checkbox"/>	<input type="text"/>

Guide:

1. The maximum number of candidates that delegates are eligible to elect is equal to the number of candidates needed to elect (01 member)
2. If accumulative elect the entire elect for one or several candidates, delegates mark in “Cumulative voting” of the corresponding candidates.
3. If the number of elections is uneven for many candidates, the delegate must specify the number of elections in the “Number of votes” of the corresponding candidates.

June 29th, 2026

DELEGATE

(Signature and full name)

Hanoi, June , 2026



**NOTICE OF NOMINATION, SELF-NOMINATION , AND ELECTION
FOR SUPPLEMENTARY MEMBER OF THE BOARD OF DIRECTORS
FOR THE REMAINING 2024 – 2029 TERM**

Pursuant to:

- *The Law on Enterprises No. 59/2020/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on June 17, 2020, as amended and supplemented by Law No. 03/2022/QH15 passed by the National Assembly on January 11, 2022, and its guiding documents, Law No. 76/2025/QH15 adopted by the National Assembly on June 17, 2025, and the guiding documents;*
- *The Law on Securities No. 54/2019/QH14 passed by the National Assembly of the Socialist Republic of Vietnam on November 26, 2019, as amended by Law No. 56/2024/QH15 passed by the National Assembly on November 29, 2024, and its guiding documents;*
- *Decree No. 155/2020/ND-CP dated 31 December 2020 of the Government detailing the implementation of a number of articles of the Law on Securities, as amended and supplemented by No. 245/2025/ND-CP dated 11 September 2025, and its guiding documents;*
- *The Charter on Organization and Operation of Mediplantex National Pharmaceutical Joint Stock Company;*
- *The Company's Internal Regulation on Corporate Governance, the Operational Regulations of the Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company;*

The Board of Directors of Mediplantex National Pharmaceutical Joint Stock Company hereby notifies the esteemed shareholders of the specific regulations regarding the nomination and self-nomination for the election of additional member to the Board of Directors for the remaining 2024 – 2029 term, as follows:

**I. ELECTION ADDITIONAL MEMBERS OF THE BOARD OF DIRECTORS
FOR THE REMAINING 2024 – 2029 TERM**

- Number of additional members of the BOD to be elected (expected): **01 member**.
- Term of the additional member: The remaining duration of the 2024–2029 term.
- Structure of the Board of Directors:

The structure of the Board of Directors must ensure that at least one-third (1/3) of the total number of Board members are non-executive members (i.e., members of the Board of Directors who are not the General Director, Deputy General Directors, Chief Accountant, or other executive managers as defined by the Company's Charter).

The number of independent member of the Board of Directors must be at least 01 member.

II. CRITERIA AND CONDITIONS FOR NOMINATION AND SELF-NOMINATION OF MEMBERS OF THE BOARD OF DIRECTORS FOR THE 2024 - 2029 TERM

1. Criteria and Conditions for Member of the Board of Directors: Members of the Board of Directors shall meet the qualifications and eligibility requirements set out in Article 155 of the 2020 Law on Enterprises, Article 275 of Decree No. 155/2020/ND-CP, Clause 78, Article 1 of Decree No. 245/2025/ND-CP, and Article 10 of the Company's Internal Regulations on Corporate Governance.

2. Criteria for Independent Members of the Board of Directors: Independent members of the Board of Directors shall meet the qualifications and eligibility requirements set out in Clause 2, Article 155 of the Law on Enterprises and Article 7 of the Regulation on Operations of the Board of Directors

3. Nomination and Candidacy of Candidates for the Board of Directors (Pursuant to Clause 5, Article 115 of the Law on Enterprises and Article 28 of the Company's Charter)

a. Shareholders holding ordinary shares shall have the right to aggregate their voting rights for the purpose of nominating candidates to the Board of Directors. Shareholders or groups of shareholders holding 10% or more of the total number of ordinary shares shall have the right to nominate candidates for election to the Board of Directors, as follows:

- A shareholder or group of shareholders holding from 5% to less than 10% of the total voting shares may nominate one (01) candidate;
- A shareholder or group of shareholders holding from 10% to less than 30% of the total voting shares may nominate up to two (02) candidates;
- A shareholder or group of shareholders holding from 30% to less than 40% of the total voting shares may nominate up to three (03) candidates;
- A shareholder or group of shareholders holding from 40% to less than 50% of the total voting shares may nominate up to four (04) candidates;
- A shareholder or group of shareholders holding from 50% to less than 60% of the total voting shares may nominate up to five (05) candidates;
- A shareholder or group of shareholders holding from 60% to less than 70% of the total voting shares may nominate up to six (06) candidates;
- A shareholder or group of shareholders holding from 70% to less than 80% of the total voting shares may nominate up to seven (07) candidates;

01
C
CC
TC TR
EDIP
M
PHO

- A shareholder or group of shareholders holding from 80% to less than 90% of the total voting shares may nominate up to eight (08) candidates.
- b. Ordinary shareholders forming a group to nominate candidates to the Board of Directors must notify the shareholders attending the General Meeting of Shareholders of such grouping prior to the opening of the General Meeting of Shareholders.
- c. In the event that the number of candidates for the Board of Directors nominated and self-nominated remains insufficient, the incumbent Board of Directors may nominate additional candidates or organize nominations in accordance with a mechanism specified in the Company's internal corporate governance regulations. This nomination mechanism or the procedure for nomination by the incumbent Board of Directors must be clearly disclosed and must be approved by the General Meeting of Shareholders prior to its implementation.

III. NOMINATION AND SELF-NOMINATION DOCUMENTS:

Shareholders or groups of shareholders holding the required percentage as stipulated above, when nominating or applying as candidates for the Board of Directors of the Company, must submit the following documents to the Company either in person or by postal mail:

- Self-Nomination or nomination letter for candidacy to the Board of Directors (using the attached form);
- Information disclosure form (using the attached form);
- Copies of the candidate's legal identification documents;
- Minutes of the shareholders' group meeting (in case a group of shareholders aggregates voting shares to nominate a Board member) (using the attached form);
- Certified copies of relevant academic qualifications (if any) of the candidate/nominee.

IV. DEADLINE AND ADDRESS FOR SUBMISSION OF SELF-NOMINATION/ NOMINATION DOCUMENTS

For the convenience of organizing the election process and preparing election materials, the Company respectfully requests eligible shareholders/shareholder groups wishing to nominate or stand for election to submit by fax or email the nomination/self-nomination dossier as prescribed in Section III above, and concurrently send the original dossier to the Company no later than 3:00 p.m. on 18 June 2026, using the following contact information:

- Contact Address: Mediplantex National Pharmaceutical Joint Stock Company – 358 Giai Phong Street, Phuong Liet Ward, Hanoi.
- Contact Person: Ms. Chu Huyen Trang – Position: Company Secretary.
- Tel: 024.38643360 / 0916117939
- Email: trang.chuh@mediplantex.com.

2025
CÔNG
PHÁ
UNG L
.ANTE
HÀ N

In the event that a shareholder or group of shareholders fails to submit the original copies of the self-nomination/nomination documents as stipulated in Section IV above to the Company prior to the approval of the list of nominees/candidates at the General Meeting, such self-nomination/nomination shall be deemed non-compliant with the provisions of the Law on Enterprises and the Company's Charter, and consequently, the self-nomination/nomination shall be considered invalid at the General Meeting.

Based on the nomination and self-nomination dossiers submitted by shareholders and groups of shareholders, together with the supporting documents of the candidates, the Board of Directors shall compile a list of candidates who satisfy the prescribed eligibility requirements and submit such list to the General Meeting of Shareholders for approval prior to the election of members of the Board of Directors. If, by the date preceding the opening of the General Meeting of Shareholders, the number of nominated and self-nominated candidates for the Board of Directors is less than the number of Board members to be elected, the remaining candidates shall be nominated by the Board of Directors or through a nomination process organized in accordance with applicable laws and the Company's Charter.

OB. BOARD OF DIRECTORS
CHAIRMAN

Nguyen Ngoc Xuan Trang

